Emerging evidence has suggested that N6-methyladenosine (m6A) modification, a typical RNA methylation modification, controls the fate of modified transcripts and is involved in the pathogenesis of various human diseases, such as metabolic disorders, nephropathology, osteoarthritis and malignant tumours. Long noncoding RNAs (lncRNAs), transcripts of >200 nt in length, have also been indicated to be involved in various diseases by participating in processes such as epigenetic modifications, transcriptional alternations and posttranslational regulation. Recent studies revealed that lncRNAs were widely modified by m6A, which has a critical role in various cellular processes that are associated with numerous disorders, particularly human cancers. The present review first examined functions of m6A modification of lncRNAs, including changing the lncRNA structure, mediating transcriptional regulation, affecting mRNA precursor splicing, and regulating lncRNA stability and translation. Furthermore, the regulatory mechanisms of m6A-modified lncRNAs in cancers were summarized and the up-to-date detection methods and prediction tools for identifying m6A sites on lncRNAs were presented. In addition, viewpoints on potential future directions in the field were discussed, including more accurate detection methods, roles of lncRNAs-encoded micropeptides in cancers, the relationship

Key words: m6A, lncRNA, aberrant expression, cancer, biomarker
between m6A-modified IncRNAs and the tumour microenvironment, and m6A-modified IncRNAs as potential biomarkers and therapeutic targets in human cancer.

Contents

1. Introduction
2. Regulators of m6A modification
3. Functions of IncRNAs after m6A modification
4. Roles of m6A-modified IncRNAs in cancers
5. Detection methods and tools to predict m6A sites on IncRNAs
6. Conclusion and future perspectives

1. Introduction

In parallel to DNA and protein, there are >170 types of biochemical modifications that occur in RNA (1,2). The most remarkable RNA modification is methylation. Numerous studies have indicated that methylation modifications are able to alter RNA structure, stability and function. These modifications include 7-methylguanine, 5-methylcytosine, N6,2’-O-dimethyladenosine (m6Am), N7-methyladenosine (m1A), 5-hydroxymethylcytosine and N6-methyladenosine (m6A) (3-5). Since 1974, m6A has been gradually identified as the most abundant modification in human RNAs (6) and has been proven to affect numerous functional processes of RNAs, such as alternative splicing (7-9), decay (10), subcellular distribution (11) and translation (12).

Mostly transcribed from DNAs, long noncoding RNAs (lncRNAs) have roles in the pathogenesis, accumulating evidence has focused on m6A-modified ncRNAs (34). Similar to METTL3, METTL16 contains the Rossmann-like fold of class I methyltransferases and uses SAM as the methyl donor but appears to have additional regulatory and RNA binding domains (35). Consistent with studies that focus on dysregulated m6A writers, abnormal IncRNAs interacting with writers have been identified in various cancers (36,37).

Erasers. M6A modification is reversible and erasers have important roles in its reversion. Two essential erasers, namely fat mass and obesity-associated protein (FTO) and AlkB homologue 5 (ALKBH5) (23,38), belong to the α-ketoglutarate- (α-KG)-dependent ALKB dioxygenase family and clear m6A methylation in an Fe(II)- and α-KG-dependent manner (39). First, they oxidize m6A to form N6-formyladenosine (hm6A). Next, they catalyse the conversion of hm6A to N4-formyladenosine (f6A). Finally, f6A is converted to A and demethylation is completed (40).

FTO. The first m6A demethylase discovered on mRNA was FTO (38). In the nucleus, FTO demethylates m6A-modified poly(A) RNA, m6A- or m6Am-modified small nuclear RNA and m1A-modified transfer (t)RNA. In the cytoplasm, it may demethylate m6A- or m6Am-modified poly(A) RNA and m1A-modified tRNA (41).

ALKBH5. ALKBH5 is another RNA demethylase. It has been indicated that demethylation induced by ALKBH5 contributes to the dysregulation of certain oncogenic IncRNAs in tumours. Numerous clinical trials based on novel drugs targeting ALKBH5 are in progress. Of note, ALKBH5 may become a considerable target for cancer diagnosis, therapy and prognosis (23).

Readers. M6A readers, including the YT521-B homology domain (YTHD) family, heterogeneous nuclear ribonucleoprotein (HNRNP) family and insulin-like growth factor 2 mRNA binding protein (IGF2BP) family, may function as binding proteins to recognize m6A on RNAs (42). Different readers have distinct functions on methylated RNA.

YTH domain family. Among diverse readers, the YTH domain family, including YTHDF1, YTHDF2, YTHDF3, YTHDC1 and YTHDC2, has been indicated to interact with m6A modification on RNAs (10). YTHDF1 promotes
the initiation of translation by interacting with eukaryotic initiation factor 3 (eIF3, which interacts with mRNA in 48S complexes and participates in the progression of translation) (43). YTHDF2 recognizes m6A sites on mRNAs and promotes their decay (44). YTHDF3 is associated with lncRNA decay (45) and recruits effectors involved in translation (46). YTHDC1 participates in m6A-mediated lncRNA-mediated gene silencing (22) and modulates the nuclear transportation of mRNA after being m6A modified (46). YTHDC2 binds to circular RNAs and interferes with their sponging of targeted microRNAs (miRNAs/miRs) (47), preferentially functioning as an m6A reader to enhance translation efficiency or decrease mRNA abundance (48).

**HNRNP family.** HNRNPs are a type of RNA binding proteins (RBPs), some of which may act as m6A readers (41). HNRNPA2/B1 binds to m6A sites to enhance the progression of primary miRNAs in an m6A-dependent manner. Furthermore, HNRNPA2/B1 may combine with certain binding sites indirectly via a mechanism called the ‘m6A switch’ (49), which means that reversible m6A modification within the RNA duplex changes the local RNA structures and accessibility for binding proteins such as HNRNPA2/B1 and HNRNPC. The function of HNRNPA2/B1 in m6A-dependent biological processes still requires further study. HNRNPC also binds to m6A-modified RNAs through an ‘m6A switch’ mechanism (21). Liu et al (50) reported HNRNPG as a novel m6A reader, as it utilizes the low-complexity region for the recognition of m6A modification and participates in the alteration of splicing diversity.

**IGF2BP family.** IGF2BPs recognize and bind RNAs with m6A modifications. Subsequently, the stability and translation of targeted RNAs may be promoted by IGF2BPs in an m6A-dependent manner, which may strongly affect gene expression levels. IGF2BP1/2/3 are newly discovered m6A readers that may protect mRNAs with m6A modifications from degradation (51). In addition, IGF2BPs stabilize the mRNAs of certain oncogenes with m6A modifications, promoting the progression of certain cancers (52).

To date, attempts have been made to illustrate the regulatory mechanisms of lncRNAs in cancers. In addition, m6A modification appears to be an upstream mechanism that regulates lncRNAs (36,37). Through the joint efforts of numerous researchers, additional m6A writers, erasers, readers and lncRNAs regulated by m6A will be discovered, which will certainly broaden our horizon regarding the functional features of m6A-modified lncRNAs in cancers.

### 3. Functions of lncRNAs after m6A modification

**Changing lncRNA structure and accessibility for proteins.** Parallel analysis of RNA structure indicated that the structure of RRACH (R=A or G; H=A, U or C) motifs that contain m6A differs from those that lack m6A modification. In vitro studies indicated that whether m6A leads to RNA secondary structure destabilization or stabilization relies upon its position within or at the edge of duplexes (53). Due to disrupting base complementary pairing between A and U, m6A modification within duplexes makes the opposite strand more single-stranded and more accessible (21). While m6A sites on lncRNAs may bind readers, localized complementary chains may also expose a U-containing binding motif for RBPs (54). In addition, reversible m6A modification changes the local structure of lncRNAs, altering the RBPs attached to lncRNAs, referred to as the ‘m6A switch’ (Fig. 2A). For instance, m6A methylation of lncRNA...
m6A‑MODIFIED lncRNAs IN CANCER

metastasis associated lung adenocarcinoma transcript 1 (MALAT1) affects its duplex structure and regulates the interaction with HNRNPC/HNRNPG, which suggests that m6A modification participates in structural switching of lncRNAs and contributes to the binding strength of proteins (21,50,54). Mediating gene transcriptional regulation. M6A‑modified lncRNAs are recognized by readers. Readers may also bind to partners that have distinct roles in transcriptional regulation, resulting in the assembly of transcriptional ribonucleoprotein complexes. Targeting activated transcriptional regions, m6A‑modified lncRNAs with transcriptional ribonucleoprotein complexes may lead to alterations in gene transcription (Fig. 2B). This mechanism requires that m6A‑modified lncRNAs may be recognized by readers and assist readers to recruit transcriptional ribonucleoprotein complexes. It is different from epigenetic regulation via methylation at promoters, whose regulation depends on methyltransferases directly binding to promoters other than m6A‑modified lncRNAs.

In this regard, Patil et al (22) provided the first example. They confirmed that m6A modification on lncRNA X‑inactive specific transcript (XIST) is recognized by YTHDC1. Subsequently, the reader YTHDC1 binds several proteins, including SMRT and HDAC associated repressor protein, lamin B receptor, HNRNPU and HNRNPK, each of which participates in transcriptional silencing. Finally, the X‑linked genes glipican 4 and α thalassemia/mental retardation syndrome X‑linked are silenced by m6A‑modified XIST binding to YTHDC1 and transcriptionally repressive proteins (22). Regulating lncRNA stability. Several studies have indicated that m6A‑modified lncRNAs exhibit differential stability and abundance compared to those without m6A modification in different types of cancer (Fig. 2D). For instance, Xue et al (58) determined that METTL3‑mediated methylation stabilizes lncRNA abhydrolase domain containing 11‑antisense RNA 1, exerting its function in non‑small cell lung cancer (NSCLC), while Guo et al (59) investigated whether ALKBH5 was able to increase the abundance of lncRNA nuclear enriched abundant transcript 1 (NEAT1) in colon cancer tissues and associated with poor prognosis. However, the upstream mechanisms by which m6A modification changes lncRNA stability and abundance are still unclear. On the one hand, m6A modification itself may change the intermolecular forces or spatial structures of local lncRNAs to affect their stability or degradation. Furthermore,
m6A regulators may interfere with RNA degradosome recognition or binding to special sites on lncRNAs, thereby regulating the process of lncRNA degradation. Specifically, writers may interfere with degrading factors binding to key sites on lncRNAs, erasers may eliminate the methyl group on lncRNAs and remove special signals recognized by degrading complexes for starting the process of RNA decomposition, and m6A readers likely recruit other partners to form complexes that interfere with the degradation of m6A-modified lncRNAs.

Regulating IncRNA translation. Due to the lack of canonical open reading frames (ORFs >100 aa), IncRNAs are considered untranslatable (60,61). Of note, a study identified hundreds of short or small ORFs (sORFs or smORFs) in the sequence of lncRNAs that actually encode peptides (62). Mechanistically, certain m6A motifs on lncRNAs may be close to crucial sequences of sORFs or smORFs. M6A readers not only recognize m6A modification on lncRNAs but also recruit translation factors at the same time. As a result, micropeptides encoded by lncRNAs are produced in an m6A-dependent manner (Fig. 2E). Wu et al (63) indicated that the YTHDF1 reader, which interacts with the translation machinery, promotes protein translation and recognizes m6A modification on lncRNA LINC00278. This m6A motif is near the stop codon of a LINC00278-encoded micropeptide, which is termed yin-yang 1 (YY1)-blocking micropeptide (YY1BM). Subsequently, YY1BM is translated in an m6A-dependent manner, ultimately resulting in apoptosis of esophageal squamous cell carcinoma (ESCC).

Despite these findings, numerous points remain to be elucidated, e.g., how m6A influences lncRNA translation. Recently, a genome-wide study identified ~100 lncRNA-encoded micropeptides that regulate induced pluripotent stem cell growth (64). However, whether m6A modification participates in lncRNA translation and micropeptide roles in cancerous cells still requires extensive validation. In addition, m6A modification has been indicated to promote mRNA export from the nucleus and it has been suggested that m6A modification may affect the subcellular diffusion of lncRNAs. For instance, Wu et al (65) reported that upregulated METTL3 subsequently localizes lncRNA RP11 primarily in the nucleus. However, how m6A modification alters the subcellular distribution of lncRNA remains elusive and requires further study.

4. Roles of m6A-modified lncRNAs in cancers

In recent decades, emerging evidence has emphasized the essential role of m6A-modified lncRNAs in cancers, which has laid a solid foundation for future clinical applications targeting m6A-modified lncRNAs, even if their mechanisms of pathogenesis differ. Below, a brief review of relevant research in this area is provided (Fig. 3).

Musculoskeletal system

Osteosarcoma (OS). Originating from mesenchymal cells, OS is one of the most aggressive tumour types in the musculoskeletal system (66). Multiple studies have revealed that dysregulated m6A-modified lncRNAs may participate in multiple phenotypes in OS. Chen et al (67) indicated that lncRNA PVT1, an oncogenic lncRNA verified in different tumour types, is upregulated in patients with OS. The m6A demethylase ALKBH5 ‘erased’ the m6A mark of PVT1, subsequently decreasing the binding of PVT1 and YTHDF2, which is a common reader that promotes the decay of m6A-modified RNAs. ALKBH5-induced PVT1 upregulation promoted OS development both in vitro and in vivo. The study’s conclusion suggests that ALKBH5-PVT1 may be a potential biomarker for OS (67). Evidence is emerging that m6A abundance and lncRNA abnormalities are involved in OS (68,69), indicating that m6A-modified lncRNAs may be better biomarkers for cancer. This provides a future direction for OS therapy that warrants further investigation.

Digestive system

Esophageal cancer (EC). EC is regarded as a globally common invasive tumour type in the digestive tract with a 5-year overall survival rate of ~20-30% (70). With the development of detection techniques, the role of m6A-modified lncRNAs in EC has been gradually revealed. Wu et al (63) indicated that smoking leads to ALKBH5 upregulation and removes m6A marks on the Y-linked lncRNA LINC00278. The classical m6A modification motif of LINC00278 that interacts with YTHDF1 is near the stop codon of YY1BM and the neighbouring YTHDF1 facilitates translation of the micropeptide YY1BM. YY1BM suppresses the transcription of eukaryotic elongation factor 2 kinase by blocking contact between YY1 and androgen receptor, resulting in apoptosis of ESCC. Mechanistically, smoking inhibits YY1BM translation, correspondingly inducing male ESCC progression (63). It is foreseeable that a deeper understanding of the complexity of m6A-modified lncRNAs involved in EC will offer novel and promising applications for EC management in the future.

Gastric cancer (GC). GC is the third most common cause of cancer-associated mortality worldwide (71). Previous studies on the dysregulation of m6A-modified lncRNAs revealed their function in GC. Zhang et al (72) indicated that in response to ALKBH5 demethylation, lncRNA NEAT1 regulates the expression of enhancer of zeste homologue 2 (EZH2), a subunit of the polycomb repressive complex, by decreasing NEAT1 function as a scaffold to bind with EZH2, affecting GC invasion and metastasis. Yan et al (44) confirmed that the association of lncRNA LINC00470 and METTL3 is recognized by the YTHDF2 reader and methylated LINC00470 binding YTHDF2 decreases the stability of phosphatase and tensin homolog (PTEN) mRNA, which encodes PTEN protein and acts as a classical tumour suppressor. M6A-modified LINC00470 ultimately promotes GC growth. Similarly, Yang et al (73) discovered that KIAA1429 recognizes the m6A site of LINC00958 and represses the decay of LINC00958, subsequently enhancing the cooperation of LINC00958 and glucose transporter-1 (GLUT1) mRNA to enhance its mRNA stability. Functionally, KIAA1429-mediated LINC00958 participates in GC tumour progression by upregulating GLUT1, which promotes aerobic glycolysis in GC. Hu and Ji (74) revealed that METTL14-mediated methylated upregulates levels of lncRNA LINC01320, which subsequently sponges miR-495-5p and affects RAB19 expression, ultimately regulating the process of lncRNA degradation. Specifically, KIAA1429-mediated LINC00958 upregulates levels of lncRNA LINC01320, which subsequently sponges miR-495-5p and affects RAB19 expression, ultimately regulating the process of lncRNA degradation.
Figure 3. M6A-modified lncRNAs in different cancer types. In glioma, m6A-modified MALAT1 activated the NF-κB pathway, leading to IDH-wildtype glioma cell proliferation and migration. In HNSCC, METTL3 and METTL14-mediated methylation increased LNCAROD stability, contributing to HNSCC cell proliferation and mobility. In TC, m6A-modified HAGLR may be recognized by IGF2BP2, inhibiting TC cell apoptosis and cell cycle arrest. In BRCA, METTL14 methylated LNC942, leading to BRCA epithelial to mesenchymal transition (EMT) and chemoresistance; METTL3-mediated m6A modification increased LINC00958 stability, finally leading to therapy resistance; METTL3 modified MALAT1, facilitating BRCA cell stemness. In OS, ALKBH5 demethylated PT1 and decreased YTHDF2 recognition of the m6A mark on PT1, contributing to OS growth. In CRC, m6A-modified GAS5 may be recognized and degraded by YTHFD2, contributing to CRC growth; METTL3-modified RP11 may be recognized by HNRNPA2B1, promoting CRC metastasis; ALKBH5-induced demethylation increased NEAT1 expression, correlating with poor prognosis of CRC. METTL14-modified XIST may be recognized and degraded by YTHFD2, inhibiting CRC invasion. In PC, ALKBH5-mediated demethylation upregulated KCN15-AS1 expression, resulting in EMT of PC; m6A-modified DANC1R may be recognized and stabilized by IGF2BP2, leading to PC stemness-like properties. In gynaecological cancers, m6A-modified FENDRR may be recognized and degraded by YTHFD2, resulting in endometrioid endometrial carcinoma cell proliferation; m6A modification increased RHPN1-AS1 stability, contributing to epithelial ovarian cancer growth; METTL3 methylates ZFAS1, thus enhancing cervical cancer metastasis; m6A-modified KCNMB2-AS1 may be recognized and stabilized by IGF2BP3, promoting cervical cancer growth. In haematological malignancies, m6A-modified MALAT1 promoted chimeric mRNA exportation, contributing to myeloid progenitor cell differentiation in malignant haematopoiesis; METTL3 elevated NEAT1 stability, finally releasing chronic myelocytic leukaemia cells from cell cycle arrest; decreased m6A methylation of TRERNA1 regulated by ALKBH5 was indicated to regulate diffuse large B-cell lymphoma cell proliferation. In PCa, VIRMA is associated with CCA1 and CAT2, indicating poor prognosis of PCa. In KC, IGF2BP2 recognized MTC-mediated m6A modification on DUXAP9 and stabilized it, ultimately triggering EMT of clear renal cell carcinoma. In HCC, METTL3 mediated LINC00958 upregulation, promoting HCC lipogenesis and development; METTL3 induced decay of MEG3, resulting in HCC growth; m6A-modified IncAY may be recognized and degraded by YTHFD2, ultimately suppressing HCC cell proliferation and migration; m6A modification increased NFK-AS1 expression, mediating HCC metastasis and therapeutic resistance. In EC, ALKBH5 removed m6A marks of LINC00278, finally inhibiting esophageal squamous cell carcinoma cell apoptosis. In GC, ALKBH5 demethylated NEAT1, affecting GC invasion and metastasis; METTL3 methylated LINC00470 may be recognized by YTHFD2, ultimately promoting GC growth; KIAA1429 repressed the decay of LINC00958, finally regulating GC metabolism reprogramming; METTL14 mediated LINC01320 upregulation, contributing to an aggressive phenotype of GC. In LC, METTL3-modified MALAT1 may be recognized by YTHFD3, resulting in poor prognosis of NSCLC; m6A modification upregulated FEZF1-AS1 expression, leading to NSCLC cell proliferation and invasion; METTL3 elevated LCAT3 stability, contributing to LUAD oncogenesis; ALKBH5 upregulated RMRP expression, inhibiting LUAD cell apoptosis. In NPC, METTL3-mediated modification elevated FAM225A stability, ultimately promoting metastasis of NPC. m6A, N’-methyladenosine; METTL3, methyltransferase-like 3; MTC, m6A methyltransferase complex; VIRMA, vir-like m6A methyltransferase associated; ALKBH5, AlkB homologue 5; YTHFD, YT521-B homology domain; HNRNP, heterogeneous nuclear ribonucleoprotein; IGF2BP, insulin-like growth factor 2 mRNA binding protein; HNSCC, head and neck squamous cell carcinoma; TC, thyroid cancer; BRCA, breast cancer; OS, osteosarcoma; CRC, colorectal cancer; PC, pancreatic cancer; PCa, prostate cancer; KC, kidney cancer; HCC, hepatocellular carcinoma; EC, esophageal cancer; GC, gastric cancer; LC, lung cancer; NSCLC, non-small cell lung cancer; LUAD, lung adenocarcinoma; NPC, nasopharyngeal carcinoma.
Colorectal cancer (CRC). CRC remains one of the most common neoplasms in the lower digestive tract globally. In China, CRC is also a major cause of tumour-associated mortality (75). Researchers have identified numerous m6A-modified lncRNAs related to the tumorigenesis and metastasis of CRC. Ni et al (76) revealed that lncRNA GAS5 binds to the WW domain of yes-associated protein (YAP) directly and subsequently leads to phosphorylation and ubiquitin-mediated decomposition of YAP, inhibiting CRC progression. However, the m6A reader YTHDF2 facilitates m6A-modified GAS5 degradation and reverses YAP-mediated inhibition of tumour progression. Wu et al (65) discovered that METTL3-mediated methylation of lncRNA RP11 is recognized by HNRNPA2B1. After binding with HNRNPA2B1, m6A-modified RP11 facilitates the decay of seven in absentia homolog 1 (SIAH1) and F-box only protein 45 (FBXO45) mRNA, possibly through HNRNPA2B1 recruiting factors that participate in the mRNA degradation process, such as P bodies. The mRNA of SIAH1 and FBXO45 encodes proteins that function as ubiquitin E3 ligases and further mediate zinc finger E-box binding homeobox 1 protein degradation via the ubiquitin-proteasome pathway. In this way, m6A-modified RP11 and accelerated mRNA degradation trigger the dissemination of CRC. Guo et al (59) indicated that ALKBH5 increased lncRNA NEAT1 expression in colon cancer tissues and was associated with poor prognosis. Yang et al (77) reported that m6A-modified XIST, an oncogenic lncRNA, is degraded after recognition by the m6A reader YTHDF2. Furthermore, METTL14 suppresses the proliferation and invasion of CRC cells by degrading XIST in an m6A-dependent manner. Further exploration of m6A-related lncRNAs in CRC is necessary to lay a solid foundation for their future use in CRC diagnosis and treatment.

Hepatocellular carcinoma (HCC). HCC remains the most common liver cancer with high morbidity globally (75). Different underlying cellular mechanisms of hepatocarcinogenesis that are governed by m6A-modified lncRNAs have been unveiled through the joint efforts of scientists. Zuo et al (36) revealed that METTL3-mediated m6A modification induces increased lipogenesis-related lncRNA LINC00958. M6A-modified LINC00958 sponges miR-3619-5p to upregulate hepatoma-derived growth factor expression, thereby facilitating HCC lipogenesis and progression. By contrast, Wu et al (78) discovered that METTL3-mediated m6A modification induced the decay of lncRNA MEG3, which affected HCC progression through the miR-544b/B-cell translocation gene 2 axis. Chen et al (79) reported a decrease in lncRNA IncAY after binding the m6A reader YTHDF2. M6A-modified IncAY downregulates B cell-specific Moloney murine leukemia virus integration site 1 (BMI1), a protein that modulates stem cell maintenance in diverse human epithelial cancers and has considerable roles in the initiation and progression of numerous cancer types. Decreasing the expression levels of BMI1 inhibited the activation of Wnt/β-catenin signalling, subsequently suppressing cell proliferation and migration of HCC. Another study suggested that m6A methylation upregulates the levels of lncRNA NIFK-AS1 in HCC (80). Furthermore, m6A-modified NIFK-AS1 functions as a competing endogenous RNA (ceRNA) to sponge miR-637, increasing AKT1 expression, which resulted in the upregulation of MMP7 and MMP9, both of which are essential mediators of metastasis and are positively associated with NIFK-AS1. It was also confirmed that by suppressing the drug transporters organic anion transporting polypeptide 1 B1 (OATP1B1) and OATP1B3, upregulated NIFK-AS1 decreased the sensitivity of HCC cells towards sorafenib, which is a multikinase inhibitor and the first targeted drug for advanced HCC approved by the Food and Drug Administration. A rapid upsurge of research publications in recent decades has occurred; exploring novel pathogenesis mechanisms and identifying new biomarkers of HCC requires further efforts for the improvement of diagnosis and treatment.

Pancreatic cancer (PC). PC is one of the most malignant tumour types and lacks specific symptoms and effective treatment (81). In recent decades, the morbidity of PC has increased 6-fold in China (82). Recent studies indicated that m6A-modified lncRNAs have critical roles in PC. He et al (83) found that lncRNA KCNK15-AS1 levels were decreased by m6A methylation and functioned as an antitumor lncRNA by inhibiting pancreatic cancer cell migration, invasion and epithelial to mesenchymal transition (EMT). As an m6A eraser, ALKBH5 mediates the increase in KCNK15-AS1 via demethylation. Owing to the higher levels of KCNK15-AS1, the antitumor effects were recovered in PC. Hu et al (84) demonstrated that the stability of lncRNA DANCRC, which was reported to promote cancer stemness-like properties, was strengthened by the interaction of IGF2BP2 with DANCRC at the A664 site in PC. As a result, m6A-mediated upregulation of DANCRC promoted cell proliferation, stemness-like properties and tumorigenesis of PC cells. In general, research in this field is progressing rapidly. With continued research on PC diagnosis, treatment and prognosis, profound changes will occur in the near future.

Respiratory system. Along with changes in the environment and lifestyle, lung cancer (LC) has gradually become the most frequently occurring cancer type (11.6% of total cases) and the major cause of cancer-associated mortality (18.4% of all cancer-associated deaths) (71,85). Studies have indicated that m6A-modified lncRNAs may serve as biomarkers for the dual purpose of timely screening and targeted therapy of lung cancer. Jin et al (37) demonstrated that METTL3-induced methylation upregulated the levels of lncRNA MALAT1 and the stability of MALAT1 was increased by the METTL3/YTHDF3 complex in NSCLC. Upon binding to METTL3-modified MALAT1, YTHDF1/3 recruits elf3b to the translation initiation complex, enhancing translation of YAP, which is associated with the development, progression and poor prognosis of NSCLC. Furthermore, MALAT1 functions as a ceRNA to sponge miR-1914-3p and inhibit its binding to the 3'-untranslated region (3'-UTR) of YAP mRNA to decrease YAP expression. Finally, m6A-modified MALAT1 facilitates malignant phenotypes of NSCLC cells. Similarly, Song et al (86) discovered that the m6A-modified IncRNA FEZF1-AS1 facilitates NSCLC progression via the miR-516b-5p/ITGA11 axis. Qian et al (87) reported that m6A modification mediated by METTL3 contributes to the increasing level and enhanced stability of IncRNA LCAT3 in lung adenocarcinoma (LUAD). LCAT3 interacts with far upstream element binding protein 1 (FUBP1), resulting in
activation of c-Myc expression, which is a typical oncogenic transcriptional factor. Thus, LCAT3 promotes malignant phenotypes of LUAD cells via the FUBP1/c-Myc axis. Yu and Zhang (88) observed that ALKBH5 upregulated lncRNA RMRP expression via demethylation in both patients with LUAD and cell lines, conveying a poorer prognosis of LUAD. Despite numerous challenges, it is thought that m6A-modified lncRNAs have the potential to be applied in the diagnosis and therapy of LC.

Urinary system. Kidney cancer (KC) is the 14th most common malignancy worldwide (89). Aberrant m6A modification-related lncRNAs that may be involved in the progression of KC remain to be elucidated. Tan et al (90) revealed that by binding with IGF2BP2, the lncRNA DUXAP9 becomes stabilized in clear-cell renal cell carcinoma (ccRCC) in an m6A-dependent manner. Subsequently, DUXAP9 activates PI3K to induce Akt/mTOR signalling, which is common in the regulation of cell growth. Meanwhile, Akt activation phosphorylates and thereby inhibits glycogen synthase kinase 3β (GSK3β) function, which phosphorylates Snail and mediates Snail nuclear export and degradation. As a result, DUXAP9 was demonstrated to trigger EMT in ccRCC cells via the Akt/GSK3β/Snail axis. In summary, m6A-modified DUXAP9 promotes proliferation and EMT in renal cancer cells.

Reproductive system
Prostate cancer (PCa). PCa is the most commonly diagnosed cancer in males and the 5-year survival rate of patients with PCa with distant metastasis is as low as ~30% (91). Currently, a comprehensive analysis of how m6A-modified lncRNAs function in the clinicopathological characteristics, malignant progression, and prognosis of PCa is lacking. Barros-Silva et al (92) demonstrated that VIRMA, a subunit of MTC, is the most common writer in PCa, and m6A methylation may stabilize lncRNA CCAT1 and lncRNA CCAT2, which participate in the alteration of the proto-oncogene MYC. Regarding clinical relevance, VIRMA and upregulation of both lncRNAs (CCAT1 and CCAT2) predict worse disease-free survival. Although their roles are not entirely understood, m6A-modified lncRNAs in PCa are thought to be very attractive biomarkers for early diagnosis, targeted therapy and improved prognosis in the future.

Breast cancer (BRCA). According to GLOBOCAN 2020, BRCA is the most commonly diagnosed cancer and the leading cause of cancer-associated death in females (71). Recently, solid evidence has led to research on the role of m6A-modified lncRNAs in BRCA. Sun et al (93) found that METTL14 recognizes and binds lncRNA LNC942 at a specific motif. Thereafter, METTL4-methylated LNC942 promotes the mRNA stability and expression of CXC4 and CYP1B1, which induce EMT and drug resistance, respectively. Finally, m6A-modified LNC942 mediates BRCA cell vitality and EMT. Rong et al (94) revealed that METTL3-mediated m6A modification promotes the stability of LINC00958. Moreover, m6A-modified LINC00958 acts as a ceRNA to sponge the miR-26b/miR-4294 and positively regulate YY1, which is involved specifically in metastasis, chemoinmunoresistance and EMT. Thus, m6A-modified LINC00958 promotes the tumour progression of BRCA cells via the miR-378a-3p/YY1 axis. Likewise, Zhao et al (95) found that the METTL3-modified lncRNA MALAT1 facilitates the pathogenesis of BRCA through the miR-26b/miR-4294 axis. HMGA2 is a transcriptional regulator that is known to promote stemness, aggression and tumour heterogeneity. The differential expression of m6A-related lncRNAs in BRCA makes them exciting candidates for diagnostic markers or therapeutic targets for BRCA.

Gynaecological cancers. Gynaecological cancers originate from and affect women's reproductive organs, while endometrial, ovarian and cervical cancers are the most frequent and major gynaecological cancers in females (96). Studies have indicated that m6A-modified lncRNAs have pivotal roles in the tumorigenesis and metastasis of gynaecological cancers. Shen et al (97) observed that abundant m6A modification increases the degradation of lncRNA FENDRR by recruiting the m6A reader YTHDF2 in endometrial endometrial carcinoma (EEC). Subsequently, downregulation of lncRNA FENDRR results in the accumulation of SOX4 protein, which is reported to promote the proliferation of EEC cell lines via epigenetic repression of miR-129-2. Thus, m6A-modified FENDRR boosts the proliferation of EEC cells and further aggravates the pathological process of EEC. Wang et al (98) discovered that m6A upregulates the levels of lncRNA RHPLN1-AS1 by decreasing RNA decay in epithelial ovarian cancer (EOC). Subsequently, RHPLN1-AS1 acts as a ceRNA to sponge miR-596, consequently increasing leucine zipper/EF hand-containing transmembrane-1 (LETM1) expression, which has an oncogenic role as an activator of the focal adhesion kinase (FAK)/P13K/Akt pathway in EOC. Therefore, RHPLN1-AS1 facilitates EOC cell growth and metastasis via the miR-596/LETM1 axis. Likewise, Yang et al (99) revealed that METTL3 methylation is required for lncRNA ZFAS1 to sequester miR-647 by acting as a ceRNA, which was previously reported to be involved in tumour progression, ultimately resulting in enhanced cervical cancer (CC) proliferation and metastasis. Sun et al (100) also revealed that lncRNA KCNMB2-AS1 is stabilized by m6A modification and promotes CC growth by acting as a ceRNA to sponge miR-130b-5p and miR-4294. Despite these studies having contributed to the understanding of the disease pathophysiology, challenges in gynaecological cancers still require to be addressed by comprehensive research to accelerate the advancement of prognostic, diagnostic and therapeutic approaches.

Haematological system. Neoplasms of the haematopoietic and lymphoid tissues are closely linked to the circulatory and immune systems, accounting for ~9% of all cancers (101). Due to their roles in the regulation of blood cell turnover, m6A-modified lncRNAs are likely to participate in the tumorigenesis of haematopoietic malignancies. Focusing on tumorigenesis fusion proteins produced by aberrant chromosomal translocations, Chen et al (102) reported that lncRNA MALAT1 binds to these fusion proteins and is localized in nuclear speckles after m6A modification. Then, m6A-modified MALAT1 and fusion proteins serve as a functional platform for METTL14 to methylate chimeric mRNA. After binding YTHDC1, m6A-modified chimeric mRNA is exported to the cytoplasm, leading to upregulation of the fusion protein, which is involved
in the tumorigenesis of leukaemia. Yao et al (103) discovered that METTL3-mediated methylation increases the stability of lncRNA NEAT1. Subsequently, m6A-modified NEAT1 acts as a ceRNA to sponge miR-766-5p and subsequently increases levels of cyclin-dependent kinase inhibitor 1A (CDKN1A), which is the target gene of miR-766-5p and serves as a negative cell cycle regulator. Finally, m6A-modified NEAT1 suppresses the progression of chronic myelocytic leukaemia by regulating the miR-766-5p/CDKN1A axis. Song et al (104) reported that ALKBH5 decreases the m6A modification of lncRNA TRERNA1, resulting in increased TRERNA1 in diffuse large B-cell lymphoma (DLBCL). TRERNA1 then recruits EZH2 to the p21 promoter region, leading to the repression of this cyclin-dependent inhibitor. Finally, TRERNA1 regulates cell proliferation and is associated with poor prognosis in patients with DLBCL. The development of sensitive detection methods and targeted inhibitors for m6A-modified lncRNAs may have potential in the clinical management of haematological malignancies, particularly when combined with existing options.

Head and neck cancers

Head and neck squamous cell carcinoma (HNSCC). HNSCC is the sixth most frequently occurring neoplasm globally, claiming ~450,000 lives every year (91). To date, the complex molecular mechanisms of m6A-modified lncRNAs and their influence on the tumorigenesis and development of HNSCC still require to be explored. Ban et al (105) discovered that MTC-induced m6A modification increases the stability of the lncRNA LNCAROD. As a scaffold for the interaction between Y-box binding protein 1 (YBX1) and heat-shock 70-kDa protein 1A (HSPA1A), m6A-modified LNCAROD shields YBX1 from proteasomal degradation by promoting the YBX1-HSPA1A protein-protein interaction, leading to HNSCC cell growth by stabilizing the YBX1 protein. It is still necessary to verify the vital role of m6A-modified lncRNAs in HNSCC, understand the mechanisms of tumorigenesis and progression in depth and identify more effective therapeutic approaches.

Nasopharyngeal carcinoma (NPC). Due to early invasion and distant metastasis, the 5-year survival rate of NPC remains <20% (106). Accumulating studies suggest that dysregulation of m6A-modified lncRNAs has a pivotal role in the occurrence and metastasis of NPC. Zheng et al (107) identified that m6A modification improves the stability of lncRNA FAM225A. Consequently, upregulation of FAM225A facilitates its function as a ceRNA to sponge miR-590-3p and miR-1275, resulting in increased integrin β3 (ITGB3) expression, which is one of the activators in the FAK/PI3K/Akt pathway. Functionally, FAM225A has been confirmed to promote NPC tumorigenesis.

Nervous system. Characterized by high tumour heterogeneity and poor survival, gliomas appear to be one of the deadliest intracranial cancer types (108). Recently, scientists demonstrated that abnormal m6A-modified lncRNAs are associated with the occurrence and growth of gliomas. Chang et al (109) indicated that METTL3 was elevated in isocitrate dehydrogenase (IDH) wild-type glioma, and with the assistance of HuR, upregulated levels of m6A methylation increase the stability of lncRNA MALAT1. M6A-methylated MALAT1 then activates the NF-κB signalling pathway to promote the malignant progression of IDH wild-type gliomas (109). The association between m6A-modified lncRNAs and oncology is being increasingly explored, while studies in this field have the potential to lay a solid foundation for elucidating the mechanisms of brain tumours.

Endocrine system. Thyroid cancer (TC) is the most frequently occurring cancer type arising from the endocrine system and has exhibited an increasing trend in recent decades (91). However, its morbidity is significantly heterogeneous in terms of different regional factors, ethnic backgrounds and genders (110). To date, various m6A-modified lncRNAs have been studied. Dong et al (111) reported that the m6A reader IGF2BP2 recognizes m6A modification of lncRNA HAGLR and upregulates the expression and stability of HAGLR. Subsequently, elevated HAGLR markedly promotes TC cell proliferation, migration and invasion (111). The features of m6A-modified lncRNAs may be applied to the clinical management of TC and have the potential to expand the current knowledge regarding TC tumorigenesis.

Brief summary. Emerging evidence has revealed that m6A-modified lncRNAs participate in tumour cell proliferation, invasion and migration primarily through two different mechanisms: regulating lncRNA stability (58,59) and translation (63). However, fewer studies on cancers are relevant to the other three functions of m6A-modified lncRNAs, such as changing accessibility to binding proteins (50,54), mediating gene transcriptional silencing (22) and affecting mRNA gene transcriptional silencing (22) and affecting mRNA changing accessibility to binding proteins (50,54), mediating gene transcriptional silencing (22) and affecting mRNA.
Table I. Novel detection methods for m6A on long non-coding RNAs.

| Classification/method         | Author, year | Description (Refs.)                                                                                     |
|-------------------------------|--------------|----------------------------------------------------------------------------------------------------------|
| Antibody-based                |              |                                                                                                          |
| MeRIP-seq                     | Meyer, 2012  | MeRIP-seq is based on immunoprecipitation. Methylated RNAs may be recognized by specific antibodies and detected by RNA-seq after isolation and purification. (20) |
| PA-m6A-seq                    | Chen, 2015   | In PA-m6A-seq, 4SU is integrated into RNA by metabolism. In certain conditions, 4SU may interact with aromatic amino acid residues of m6A antibody. This tool vastly improves the accuracy of m6A detection. However, the application of PA-m6A-seq is limited due to the requirement of 4SU metabolism. (123) |
| miCLIP                        | Linder, 2015 | In miCLIP, RNAs with m6A modifications may bind with m6A antibody after 254 nm irradiation and induce nucleotide mismatches or truncation signatures near m6A sites in the process of reverse transcription. (124) |
| m6A-LAIC-seq                  | Dominissini, 2012 | m6A-LAIC-Seq is similar to meRIP-seq, but the spike-in RNA is introduced into the m6A sequence as an internal reference, and then the methylation level of each gene segment in the complete transcriptome is calculated. This method is performed directly with full-length transcripts for RIP as opposed to library construction without RNA fragmentation. (56) |
| Digestion-based: m6A-REF-seq/ MAZTER-seq | Zhang, 2019 | m6A-REF-seq is a novel high-throughput approach to detect m6A. The PCR database may be constructed based on the RNA particles treated with RNA endonuclease MazF. Subsequently, sequencing and analysis were performed to confirm the m6A modification site. (122) |
| Gene editing-based: DART-seq  | Meyer, 2019  | In DART-seq, certain technologies are used to make cells express apolipoprotein B mRNA-editing enzyme complex 1-YTH fusion protein. This protein may replace C of m6A with U. The m6A modification site may be confirmed by identifying the site where C-to-U editing of genomic information has taken place. (125) |
| Metabolism-based              |              |                                                                                                          |
| M6A-label-seq                 | Shu, 2020    | M6A-label-seq is able to generate a6A at the sites of m6A modifications. These a6A modifications may be recognized by antibodies and may be cyclized. Mis-incorporation induced by this cyclized a6A in reverse transcription may provide information on m6A sites at single-base resolution. (126) |
| M6A-SEAL-seq                  | Wang, 2020   | In order to detect m6A modification sites, hm6A, which is an oxidation product of m6A, is generated through a thiol addition reaction. Hm6A may form stable dm6A via interacting with DTT. Subsequently, dm6A may be enriched and subjected to sequencing. (127) |

MeRIP-seq, methylated RNA immunoprecipitation sequencing; m6A, N6-methyladenosine; PA-m6A-seq, photo-cross-linking-assisted m6A sequencing strategy; 4SU, 4-thiouridine; miCLIP, m6A individual-nucleotide resolution UV crosslinking and immunoprecipitation; m6A-LAIC-seq, m6A-level isoform-characterization sequencing; m6A-REF-seq/MAZTER-seq, m6A-sensitive RNA-endoribonuclease-facilitated sequencing; DART-seq, deamination adjacent to RNA modification targets-sequencing; a6A, N6-allyladenosine; dm6A, N6-dithiothreitolmethyladenosine; hm6a, N6-hydroxymethyladenosine; DTT, dithiothreitol; YTH, YT521-B homology; 4SU, 4-thiouridine.
Table II. Updated prediction tools for m6A on lncRNAs.

| Method          | Author, year | Species                        | Strength                                                                 | Weblink                                      | Motif restriction | (Refs.) |
|-----------------|--------------|--------------------------------|--------------------------------------------------------------------------|----------------------------------------------|-------------------|---------|
| SRAMP           | Zhou, 2016   | Mammals                        | The m6A modification sites may be recognized by SRAMP, which may supply rational predicted results. | http://www.cuilab.cn/sramp                    | DRACH             | (128)   |
| RNA-MethylPred  | Jia, 2016    | Human, mouse                   | RNA-MethylPred is capable of distinguishing m6A sites that cannot be readily detected by RNA-Methyl and pRNA-pm-PC. | -                                            | -                 | (129)   |
| Targetm6A       | Li, 2016     | -                              | The Targetm6A method outperforms the above methods for predicting m6A sites and markedly improved the prediction performance. | http://csbio.njust.edu.cn/bioinf/TargetM6A   | GAC               | (130)   |
| RMBase V2.0     | Xuan, 2018   | Human, rhesus monkey, chimpanzee, rat, pig, zebrafish, fly, *S. cerevisiae*, *A. thaliana*, *S. pombe*, *E. coli*, *P. aeruginosa* | The RMBase V2.0 database comprises >100 RNA modification forms, includes comprehensive and complex information on post-transcriptional modifications of RNA, and provides various interfaces and graphic visualizations to promote the analysis of different modification sites in normal tissues and cancer cells. | http://rna.sysu.edu.cn/rmbase                 | RACH              | (131)   |
| M6AVar          | Zheng, 2018  | Human, mouse                   | M6AVar is a user-friendly and specific database to explore the function of variations with m6A modification. It may provide detailed explanations and genomic locations of m6A modification sites. This tool may also perform analyses of RBP-binding regions, miRNA targets and splicing sites. M6AVar may also identify the functional disease-related variations. | http://m6avar.renlab.org                     | DRACH             | (132)   |
| DEEPM6ASeq      | Zhang and Hamada, 2018 | Human, mouse, zebrafish | Based on a deep learning framework to predict m6A-containing sequences and characterize biological features around m6A sites, DEEPM6ASeq exhibited an improved performance as compared with others, and it is competitive at predicting m6A-containing sequences. This model may recognize the position preference of sequences harboring m6A sites, function of motif detectors and saliency maps. | https://github.com/rreybeyb/DeepM6ASeq       | DRACH             | (133)   |
| CVm6A           | Han, 2019    | Human, mouse                   | CVm6A collects available MeRIP-Seq and m6A-CLIP-Seq datasets in human and mouse cell lines and provides a visualized m6A database to benefit functional studies on m6A in cell lines. | http://gb.whu.edu.cn:8080/ CVm6A            | RRACH             | (134)   |
HE et al.: m6A-MODIFIED lncRNAs IN CANCER

segments for sequencing (20), which is widely used in investigating methylated RNAs (114,115).

In addition, bioinformatics is a powerful tool that is able to identify likely RNA methylation sites based on statistical evidence (Table II). Among these public databases for prediction, SRAMP and m6A2Target appear to be applied more widely (116,117). Of note, LITHOPHONE is a computational framework specifically designed for predicting m6A sites of lncRNAs (118). In addition, the use of public databases may allow researchers to reduce the cost of preliminary investigations and facilitate experimental design.

Although m6A detection and prediction methods are continuously improving, it is urgent to develop more accurate methods to identify or predict m6A sites on lncRNAs. In addition, public databases to explore m6A-modified lncRNAs must be established to broaden the horizon regarding their association with biological features of human cancers.

6. Conclusion and future perspectives

In conclusion, m6A modification of lncRNAs has pivotal roles in gene expression through several mechanisms, including the adaptation in structure and binding proteins of lncRNAs, direct and/or indirect regulation of transcription, alteration of mRNA precursor splicing and change of lncRNA stability and translation. Undoubtedly, lncRNAs modified by m6A writers, erasers or readers are involved in the development and progression of various human malignancies. However, further investigations are required in the following aspects.

Previous studies have indicated that certain lncRNAs encode micropeptides (63). However, the role of m6A in this process remains to be elucidated and the mechanisms involved remain to be explored. More importantly, whether m6A modification of lncRNAs represents a marker for predicting the coding potential of lncRNAs requires to be investigated in the future (119). In addition, the role of these micropeptides encoded by m6A-modified lncRNAs in tumour development should be examined (120).

The tumour microenvironment remains a hot spot in cancer research and a number of studies have identified lncRNAs as key regulators in the tumour microenvironment (121). However, only a small number of investigations have focused on the function of m6A-modified lncRNAs in the tumour microenvironment. It is possible that single-cell sequencing technology is used to scrutinize the m6A-modified lncRNAs in different cell types of the tumour microenvironment.

Current detection procedures of m6A-modified lncRNAs are complex and lack single molecule resolution. The technologies to quantify m6A-modified lncRNAs are also limited (122). For instance, transcriptome-wide m6A-seq methods frequently require a large amount of RNA, so it is difficult to apply in clinical practice due to the limitation of patient-derived samples. It is necessary to establish new detection approaches, which allow the detection of m6A-modified lncRNAs at a low concentration such as in tumour tissues, circulating tumour cells, exosomes and faeces, and a more comprehensive public database to collect information of lncRNAs modified by m6A, which will facilitate the investigation of m6A-modified lncRNAs as regulators, biomarkers and potential therapeutic targets in human cancer.
Acknowledgements
Not applicable.

Funding
The project was supported by the National Natural Science Foundation of China (grant no. 81773187), Tianjin High School Program for Young and Middle-aged Talents Backbone and Tianjin Young Medical Talents Program and the Tianjin Commission Scientific Research Plan Project (grant no. 2018KJ064).

Availability of data and materials
Not applicable.

Authors’ contributions
YH and XD drafted the manuscript and completed the visualization. MC performed the literature search and selection, and conducted project administration and funding acquisition. All authors read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Liu J and Jia G: Methylation modifications in eukaryotic messenger RNA. J Genet Genomics 41: 23‑34, 2014.
2. Boccaletto P, Machnicka MA, Purta E, Piatkowski P, Baginski B, Wirecki TK, de Crzey‑Lagard V, Ross R, Limbach PA, Potter A, et al: MODOMICS: A database of RNA modification pathways. 2017 update. Nucleic Acids Res 46: D303‑D307, 2018.
3. Li J, Yang X, Qi Z, Sang Y, Liu Y, Xu B, Liu W, Xu Z and Deng Y: The role of mRNA m(6)A methylation in the nervous system. Cell Biosci 9: 66, 2019.
4. Dominissini D, Natcheragara S, Moshitch‑Moshkovitz S, Peer E, Kol N, Ben‑Haim MS, Dai Q, Di Segni A, Salmon‑Divon M, Clark WC, et al: The dynamic N(1)‑methyladenosine methylome in eukaryotic messenger RNA. Nature 530: 441‑446, 2016.
5. You C, Dai X and Wang Y: Position‑dependent effects of regiosomeric methylated adenosine and guanine ribonucleosides on translation. Nucleic Acids Res 45: 9059‑9067, 2017.
6. Desrochers R, Friderici K and Rottman F: Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci USA 71: 3971‑3975, 1974.
7. Bartosovic M, Molares HC, Gregorova P, Hrossova D, Kudla G and Vanacova S: N6‑methyladenosine demethylase FTO targets pre‑mRNAs and regulates alternative splicing and 3′‑end processing. Nucleic Acids Res 45: 11356‑11370, 2017.
8. Roundtree IA and He C: Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Trends Genet 32: 317‑320, 2016.
9. Xiao W, Adhikari S, Daulah U, Chen YS, Hao YJ, Sun BF, Sun HY, Li A, Ping XL, Lai WY, et al: Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Mol Cell 61: 507‑519, 2016.
10. Peng X, Lu Z, Gomez‑Fernandez Y, Yue Y, Pu Y, Parisien M, Dai Q, Jia G, et al: N6‑methyladenosine‑dependent regulation of messenger RNA stability. Nature 505: 117‑120, 2014.
11. Fustin JM, Dui M, Yamaguchi Y, Hida H, Nishimura S, Yoshida M, Isagawa T, Morikoa MS, Kakeya H, Manabe I and Okamuro H: RNA‑methylation‑dependent RNA processing controls the speed of the circadian clock. Cell 155: 793‑806, 2013.
12. Chen J, Zhang YC, Huang C, Shcn H, Sun B, Cheng X, Zhang YJ, Yang YG, Shu Q, Yang Y and Li X: m(6)A regulates neurogenesis and neuronal development by modulating histone methlytransferase Ezh2. Genomics Proteomics Bioinformatics 17: 154‑169, 2018.
13. Xu Z, Dai J, Zhang X, Xu Y, Gou Y, Liu Z, Zhao H, Yu F, Peng Y, Zhang G, et al: A comprehensive overview of IncRNA annotation resources. Brief Bioinform 18: 236‑249, 2017.
14. Peng WX, Koirala P and Mo YY: LncRNA‑mediated regulation of cell signaling in cancer. Oncogene 36: 5661‑5667, 2017.
15. Bhat SA, Ahmad SM, Muntaz PT, Malik AA, Dar MA, Urwat U, Shah RA and Ganai NA: Long non‑coding RNAs: Mechanism of action and functional utility. Noncoding RNA Res 1: 43‑50, 2016.
16. Chen F, Li Z, Deng C and Yan H: Integration analysis for novel IncRNA markers predicting tumor recurrence in human colon adenocarcinoma. J Transl Med 17: 299, 2019.
17. Zimmer‑Bensch G: Emerging roles of long non‑coding RNAs as drivers of brain evolution. Cells 8: 1399, 2019.
18. Robinson EK, Covarrubias S and Carpenter S: The how and why of IncRNA function: An innate immune perspective. Biochim Biophys Acta Gene Regul Mech 1863: 1944‑19, 2020.
19. Ma S, Chen C, Ji X, Liu J, Zhou Q, Wang G, Yuan W, Kan Q and Sun Z: The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol 12: 121, 2019.
20. Meyer KD, Saleatore Y, Zumbo P, Elemento O, Mason CE and Jaffrey SR: Comprehensive analysis of mRNA methylation reveals enrichment in 3′UTRs and near stop codons. Cell 149: 1635‑1646, 2012.
21. Liu N, Dai Q, Zheng G, He C, Parisien M and Pan T: N6‑methyladenosine‑dependent RNA structural switches regulate RNA‑protein interactions. Nature 518: 560‑564, 2015.
22. Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M and Jaffrey SR: m(6)A RNA methylation promotes XIST‑mediated transcriptional repression. Nature 537: 369‑373, 2016.
23. Zheng G, Dahl JA, Niu Y, Fedorcsak P, Huang CM, Li CJ, Vagbo CB, Shi Y, Wang WL, Song SH, et al: ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell 49: 18‑29, 2013.
24. Lan Q, Liu PY, Haase J, Bell JL, Huttelmaier S and Liu T: The critical role of mRNA methylation in cancer. Cancer Res 79: 1285‑1292, 2019.
25. Yang Y, Hsu PJ, Chen YS and Yang YG: Dynamic transcriptomic m(6)A decoration: Writers, erasers, readers and functions in RNA metabolism. Cell Res 28: 616‑624, 2018.
26. Yao L, Man CF, He R, He L, Huang JB, Xiang SY, Dai Z, Wang XY and Fan Y: The Interaction between N6‑methyladenosine modification and non‑coding RNAs in gastrointestinal tract cancers. Front Oncol 11: 784127, 2021.
27. Deng X, Su R, Weng H, Huang H, Li Z and Chen J: RNA N6‑methyladenosine modification in cancers: Current status and perspectives. Cell Res 28: 507‑517, 2018.
28. Schwartz S, Mumbach MR, Jovanovic M, Wang T, Maciag K, Bushkin GG, Mermins P, Ter‑Ovanesyan D, Habi N, Cacciarelli D, et al: Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5′sites. Cell Rep 8: 284‑296, 2014.
29. Wen J, Lv R, Ma H, Shen H, He C, Wang J, Jiao F, Liu H, Yang P, Tan L, et al: Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self‑renewal. Mol Cell 69: 1028‑1038.e8, 2018.
30. BokarJA, ShambaughME, Polayes D, Materia AG and RottmanFM: Purification and cDNA cloning of the AdoMet‑binding subunit of the human mRNA (N6‑adenosine)‑methyltransferase. RNA 3: 1233‑1247, 1997.
31. Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, Gou Y, Huang J, Tan C, et al: Structural basis of N(6)‑adenosine methylation by the METTL3‑METTL14 complex. Nature 534: 575‑578, 2016.
32. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Liu Z, Deng X, et al: A METTL3‑METTL14 complex mediates mammalian nuclear RNA N6‑adenosine methylation. Nat Chem Biol 10: 93‑95, 2014.
33. Horiuichi K, Kawamura T, Iwanari H, Ohashi R, Naito M, Kodama T and Hamakubo T: Identification of Wilms' tumor 1-interacting protein complex and its role in alternative splicing and the cell cycle. J Biol Chem 288: 33292-33302, 2013.

34. Warda AS, Kretschmer J, Hackert P, Lenz G, Urlaub H, Höbartner C, Sloan KE and Bohnsack MT: Human METTL16 is a N6-methyladenosine (m^6A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep 18: 2004-2014, 2017.

35. Ruszkowska A: METTL16, Methyltransferase-like protein 16: Current insights into structure and function. Int J Mol Sci 22: 2176, 2021.

36. Zuo X, Chen Z, Gao W, Zhang Y, Wang J, Wang J, Cao M, Cai J, Wu J and Wang X: M6A-mediated upregulation of LINC00595 increases expression of HER2 and acts as a therapeutic target in hepatocellular carcinoma. J Hematol Oncol 13: 5, 2020.

37. Jin D, Guo J, Wu Y, Du J, Yang J, Liu X, Liu J, Pan J, Zhou J, Liu Z, Liu J and et al.: m6A RNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-195-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol 14: 32, 2021.

38. Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, Yi C, Lindahl T, Pan T, Yang YG and He C: N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol 8: 883-894, 2012.

39. Sun T, Wu R and Ming L: The role of m6A RNA methylation in cancer. Biomed Pharmacother 112: 108613, 2019.

40. Wang T, Kong S, Tao M and Ju S: The potential role of RNA N6-methyladenosine in Cancer progression. Mol Cancer 19: 88, 2020.

41. Shi H, Wei J and He C: Where, When, and How: Context-dependent functions of RNA N6-methyladenosine translation writers, readers, and erasers. Mol Cell 74: 640-650, 2020.

42. Frye M, Harada BT, Behm M and He C: RNA modifications modulate gene expression during development. Science 361: 1346-1349, 2018.

43. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H and He C: N6-(Methyladenosine) modulates messenger RNA translation efficiency. Cell 161: 1388-1399, 2015.

44. Zhang J, Shen L, Liang J, Guo T, Liu DF, Peng SH and Xu AM: ALKBH5 promotes colon cancer progression by decreasing methylation of the IncRNA NEAT1. Mol Cancer 19: 88, 2020.

45. Dong S, Wu Y, Liu Y, Weng H and Huang H: N^6-methyladenosine steers RNA metabolism and regulation in cancer. Cancer Commun (Lond) 41: 538-559, 2021.

46. Dominissini D, Mohshitch-Moshkovitz S, Schwartz S, Salomon-David M, Unger L, Oberstein S, Cesarkas K, Jacob-Hirsch J, Amirgalio N, Kupiec M, et al.: Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature 485: 201-206, 2012.

47. Ninomiya K, Ikawari J, Akiyama C, Adachi S, Nakatani T, Terai G, Asai K, Suzuki T and Hirose T: m^6A modification of HSATIII IncRNAs regulates temperature-dependent splicing. EMBO J 40: e107976, 2021.

48. Xue L, Li J, Lin Y, Liu D, Yang Q, Jian P and Jang J: m^6A transferase METTL3-induced IncRNA ABHD11-AS1 promotes the Wnt/β-catenin effect of non-small-cell lung cancer. J Cell Physiol 236: 2649-2658, 2021.

49. Guo T, Liu DF, Peng SH and Xu AM: ALKBH5 promotes colon cancer progression by decreasing methylation of the IncRNA NEAT1. Am J Transl Res 12: 4542-4549, 2020.

50. Bhan A, Soleimani M and Mandell SS: Long noncoding RNA and cancer: A new paradigm. Cancer Res 77: 3965-3981, 2017.

51. Okazaki Y, Furumoto M, Kasukawa T, Adachi J, Bono H, Kondo S, Nakido I, Osato N, Saito R, Suzuki H, et al.: Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature 493: 671-677, 2012.

52. Wu S, Wright M, Gogol MM, Bradford WD, Zhang N and Bazzini AA: Translation of small downstream ORFs enhances translation of canonical main open reading frames. EMBO J 39: e104763, 2020.

53. Wu S, Zhang L, Deng J, Guo B, Li F, Wang Y, Wu R, Zhang S, Lu J and Zhou Y: A novel micropeptide encoded by Y-linked LINC00278 links cigarette smoking and AR signaling in male esophageal squamous cell carcinoma. Cancer Res 80: 2790-2803, 2020.

54. Chen J, Brunner AD, Cogan JZ, Nueke JK, Fields AP, Adamson B, Itzhak DN, Li JY, Mann M, Leonetti MD and Weissman JS: Pervasive functional translation of noncanonical human open reading frames. Science 367: 1140-1146, 2020.

55. Wu Y, Yang X, Chen Z, Tian L, Jiang G, Chen F, Li J, An P, Lu L, Luo N, et al.: m^6A-induced IncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1. Mol Cancer 18: 87, 2019.

56. Biazzo A and De Paulis M: Multidisciplinary approach to osteosarcoma. Acta Orthop Belg 82: 690-696, 2018.

57. Chen S, Zhou L and Wang Y: ALKBH5-mediated m^6A demethylation of IncRNA DICER1-AS1 promotes proliferation, migration, invasion and glycolysis in prostate cancer. Bioengineered 13: 629-630, 2022.

58. Alarcón CR, Goodarzi H, Lee H, Liu X, Tava zoio S and Tavazoie SF: HRNRPA2B1 Is a mediator of m6A-dependent nuclear RNA processing events. Cell 162: 1299-1308, 2015.

59. Liu N, Zhou KJ, Parisien M, Dai Q, Diatchenko L and Pan T: N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein. Nucleic Acids Res 45: 6051-6063, 2017.

60. Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, et al.: Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol 20: 285-295, 2018.

61. Luxton HJ, Simpson BS, Mills IG, Brindle NR, Ahmed Z, Starnes K, Sparshay S, Stamm C, Whitaker HC: The oncogene metadherin interacts with the known splicing proteins YTHDC1, Sam68 and T-STAR and plays a novel role in alternative mRNA splicing. Cancers (Basel) 11: 885-887, 2019.

62. Hu Y, Tang J, Xu F, Chen J, Zeng Z, Han S, Wang F, Dong H, Huang I, Zhang Y, et al.: A reciprocal feedback between N6-methyladenosine reader YTHFD3 and IncRNA DICER1-AS1 promotes glycolysis of pancreatic cancer through inhibiting maturation of m^6A-mRNA. J Exp Clin Cancer Res 41: 69, 2022.
77. Yang Z, Zhang S, He C, Xue P, Zhang L, He Z, Zang L, Feng B, Sun J and Zheng M: METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST. Mol Cancer 19: 46, 2020.

78. Wu J, Pang R, Li M, Chen B, Huang J and Zhu Y: miR-29a promotes the proliferation, migration and invasion of hepatocellular carcinoma cell through miR-544b/BTG2 signaling. Onco Targets Ther 14: 3745-3755, 2021.

79. Chen MH, Fu LS, Zhang F, Yang Y and Wu XZ: LncAY controls BMP1 expression and activates BMP/Smad signaling axis in hepatocellular carcinoma. Life Sci 280: 119748, 2020.

80. Song H, Li H, Ding X, Li M, Shen H, Li Y, Zhang X and Zhao Q, Zhao Y, Hu W, Zhang Y, Wu X, Lu J, Li M, Li W, Zeng M and Li J: ALKBH5-mediated N6-methyladenosine demethylation of LNC942 promoting METTL14-mediated m6A modifications of IncRNA NEAT1 regulates chronic myelocytic leukemia progression via miR-766-5p/CDK1A axis. Front Oncol 11: 679634, 2021.

81. Zhong Y, Wang D, Wu D, Zhang S and Sun M: Long non-coding RNA KCNMB2-A51 stabilized by N6-Methyladenosine modification promotes cervical cancer growth through acting as a competing endogenous RNA. Cell Transplant 29: 963687920964382, 2020.

82. Ghafoori-Fard D, Rashedi M and Taheri M: Expression of non-coding RNAs in hematological malignancies. Eur J Pharmacol 875: 172976, 2020.

83. Chen YT, Xiang D, Zhao XY and Chu XY: Upregulation of lncRNA NIFP‑AS1 in hepatocellular carcinoma by m6A methylation promotes disease progression and sorafenib resistance. Cell Death Dis 11: 2021.

84. Mizrahi JD, Surana R, Valle JW and Shroff RT: Pancreatic cancer. Lancet 395: 2008-2020, 2020.

85. Yin MY, Xi LT, Liu L, Zhu JZ, Qian LJ and Xu CF: Pancreatic cancer incidence and mortality patterns in 2006-2015 and prediction of the epidemiological trend to 2025 in China. World J Clin Cases 10: 4404-4413, 2022.

86. He Y, Hu W, Wang Y, Yuan H, Lu Z, Wu P, Liu D, Tian L, Yin J, Jiang K and Miao Y: ALKBH5 inhibits pancreatic cancer motility by decreasing long non-coding RNA KCN15‑A51 metastasis. Oncotarget 8: 61552-61561, 2017.

87. Hu X, Peng WX, Zhou H, Jiang J, Zhou X, Huang D, Mo YY and Yang L: IGF2BP2 regulates DANCr by serving as an N6-methyladenosine reader. Cell Death Differ 27: 1782-1794, 2020.

88. Chen Y, Zettlo E, Guo R and Deng Y: The function of lncRNAs and their roles in tumorigenesis, diagnosis, and prognosis of lung cancer. Clin Transl Med 11: e367, 2021.

89. Song H, Li H, Ding X, Li M, Shen H, Li Y, Zhang X and Xing L: Long non-coding RNA FEZF1AS1 facilitates nonsmall cell lung cancer progression via the ITGA11/miR516b5p axis. Cancer Cell Int 21: 441, 2021.

90. Qian X, Yang J, Qi Q, Li X, Jiang C, Li J, Dong L, Ying K, Lu B, Chen E, et al: LCAT3, a novel m6A-regulated long non-coding RNA, plays an oncogenic role in lung cancer via binding with FUBP1 to activate c-MYC. J Hematol Oncol 14: 112, 2021.

91. Yu H and Zhang Z: ALKBH5-mediated m6A demethylation of lncRNA RMRP plays an oncogenic role in liver adenosarcoma. Mammo Genome 32: 195-203, 2021.

92. Hsieh JJ, Purdie MP, Signoretti S, Swanton C, Alibges L, Schmidinger M, Heng DY, Larkin J and Ficarra V: Renal cell carcinoma. Nat Rev Dis Primers 3: 17009, 2017.

93. Tan L, Tang Y, Li H, Li P, Y Cen, J Gui, C Luo, C Jao and Wei J: N6-Methyladenosine modification of LncRNA DUXAP9 promotes renal cell carcinoma proliferation and motility by activating the P3K/AKT signaling pathway. Front Oncol 11: 641833, 2021.

94. Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer Statistics, 2021. CA Cancer J Clin 71: 7-33, 2021.

95. Barros-Silva D, Lobo J, Guimarães‑Teixeira C, Carneiro I, Oliveira J, Martens‑Uzunova ES, Henrique R and Jerónimo C: VIRMA‑dependent N6‑Methyladenosine modifications regulate the expression of long non‑coding RNAs CCAT1 and CCAT2 in prostate cancer. Cancers (Basel) 12: 771, 2020.

96. Tang Y, Wang X, Wang Y, Xu Q, Qin W, Wu Y, Chen Q, et al: LINC0942 promoting METTL14-mediated m6A methylation in breast cancer cell proliferation and progression. Oncogene 39: 5333-5342, 2020.

97. Dong R, Dong Q, Qu H, Deng X, Guo F, Li Q and Sun P: m6A-induced LINC0498A promotes breast cancer tumorigenesis via the miR-378a-3p/miR140 axis. Front Cell Neurosci 13: 1347, 2020.

98. Zhang M, Zhang J and Liu Y: Comprehensive analysis of molecular features, prognostic values, and immune landscape association of m6A-regulated immune-related lncRNAs in smoking-associated lung squamous cell carcinoma. Front Genet 13: 884777, 2022.

99. Dong L, Geng Z, Liu Z, Tao M, Pan M and Lu X: IGF2BP2 knockdown suppresses thyroid cancer progression by reducing the expression of m6A-regulated long non-coding RNA HAGLR. Pathol Res Pract 225: 135530, 2021.

100. Yuan C, Liu C, Zhao S, Zhang X, Jia H, Chen B, Zhang M, Zheng Y, Zhou J and Bo Y: The role of N6-Methyladenosine‑associated IncRNAs in the immune microenvironment and prognosis of colorectal cancer. J Oncol 2022: 4689396, 2022.

101. Roman BR, Morris LG and Davies A: The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes 24: 332-336, 2017.

102. Dong L, Geng Z, Liu Z, Tao M, Pan M and Lu X: IGF2BP2 knockdown suppresses thyroid cancer progression by reducing the expression of m6A-regulated long non-coding RNA HAGLR. Pathol Res Pract 225: 135530, 2021.

103. Yuan C, Liu C, Zhao S, Zhang X, Jia H, Chen B, Zhang M, Zheng Y, Zhou J and Bo Y: The role of N6-Methyladenosine-associated IncRNAs in the immune microenvironment and prognosis of colorectal cancer. J Oncol 2022: 4689396, 2022.

104. Roman BR, Morris LG and Davies A: The thyroid cancer epidemic, 2017 perspective. Curr Opin Endocrinol Diabetes Obes 24: 332-336, 2017.
119. Wu P, Mo Y, Peng M, Tang T, Zhong Y, Deng X, Xiong F, Guo C, Wu X, Li Y, *et al*: Emerging role of tumor-related functional peptides encoded by lncRNA and circRNA. Mol Cancer 19: 22, 2020.

120. Kong S, Tao M, Shen X and Ju S: Translatable circRNAs and lncRNAs: Driving mechanisms and functions of their translation products. Cancer Lett 483: 59-65, 2020.

121. Park EG, Pyo SJ, Cui Y, Yoon SH and Nam JW: Tumor immune microenvironment lncRNAs. Brief Bioinform 23: bbab804, 2022.

122. Zhang Z, Chen LQ, Zhao YL, Yang CG, Roundtree IA, Zhang Z, Ren J, Xie W, He C and Luo GZ: Single-base mapping of m6A by an antibody-independent method. Sci Adv 5: eaax0250, 2019.

123. Chen K, Lu Z, Wang X, Fu Y, Luo GZ, Liu N, Han D, Dominissini D, Dai Q, Pan T and He C: High-resolution N(6)-methyladenosine (m(6)A) map using photo-cross-linking-assisted m(6)A sequencing. Angew Chem Int Ed Engl 54: 1587-1590, 2015.

124. Linder B, Grozhik AV, Olarerin-George AO, Meydan C, Mason CE and Jaffrey SR: Single-nucleotide-resolution mapping of m6A and m6Am throughout the transcriptome. Nat Methods 12: 767-772, 2015.

125. Meyer KD: DART-seq: An antibody-free method for global m6A detection. Nat Methods 16: 1275-1280, 2019.

126. Shu X, Cao J, Cheng M, Xiang S, Gao M, Li T, Ying X, Wang F, Yue Y, Lu Z, *et al*: A metabolic labeling method detects m6A transcriptome-wide at single base resolution. Nat Chem Biol 16: 887-895, 2020.

127. Wang Y, Xiao Y, Dong S, Yu Q and Jia G: Antibody-free enzyme-assisted chemical approach for detection of N(6)-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res 44: e91, 2016.

128. Zhou Y, Zheng P, Li YH, Zhang Z and Cui Q: SRAMP: Prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res 44: e91, 2016.

129. Jia CZ, Zhang JJ and Gu WZ: RNA-MethylPred: A high-accuracy predictor to identify N6-methyladenosine in RNA. Anal Biochem 510: 72-75, 2016.

130. Li GQ, Liu Z, Shen HB and Yu DJ: TargetM6A: Identifying N(6)-Methyladenosine Sites from RNA sequences via Position-specific nucleotide propensities and a support vector machine. IEEE Trans Nanobioscience 15: 674-682, 2016.

131. Xuan JJ, Sun WJ, Lin PH, Zhou KR, Liu S, Zheng LL, Qu LH and Yang JH: RMBase v2.0: Deciphering the map of RNA modifications from epitranscriptome sequencing data. Nucleic Acids Res 46: D327-D334, 2018.

132. Zheng Y, Nie P, Peng D, He Z, Liu M, Xie Y, Miao Y, Zuo Z and Ren J: m6AVar: A database of functional variants involved in m6A modification. Nucleic Acids Res 46: D139-D145, 2018.

133. Zhang Y and Hamada M: DeepM6ASeq: Prediction and characterization of m6A-containing sequences using deep learning. BMC Bioinformatics 19: 524, 2018.

134. Han Y, Feng J, Xia L, Dong X, Zhang X, Zhang S, Miao Y, Xu Q, Xiao S, Zuo Z, *et al*: CVm6A: A visualization and exploration database for m6A sites in cell lines. Cells 8: 168, 2019.

135. Liu K, Cao L, Du P and Chen W: im6A-TS-CNN: Identifying the N(6)-Methyladenine site in multiple tissues by using the convolutional neural network. Mol Ther Nucleic Acids 21: 1044-1049, 2020.

136. Deng S, Zhang H, Zhu K, Li X, Ye Y, Li R, Liu X, Lin D, Zuo Z and Zheng J: M6A2Target: A comprehensive database for targets of m6A writers, erasers and readers. Brief Bioinform 22: bbaa055, 2021.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.